Actively Recruiting

Phase 4
Age: 18Years +
All Genders
NCT05671991

Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease

Led by Yale University · Updated on 2025-03-04

30

Participants Needed

1

Research Sites

173 weeks

Total Duration

On this page

Sponsors

Y

Yale University

Lead Sponsor

B

Boehringer Ingelheim

Collaborating Sponsor

AI-Summary

What this Trial Is About

The main purpose of the study is to determine if empagliflozin can reduce peritoneal glucose absorption in patients with end stage renal diease (ESRD) on peritoneal dialysis. This is a randomized, placebo controlled, acute crossover study of empagliflozin in an anticipated 30 chronic PD patients, with an 8 week "pre post" open label extension in all 30 patients where they will receive empagliflozin daily.

CONDITIONS

Official Title

Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients actively undergoing peritoneal dialysis with a reliably functioning PD catheter
  • Stable peritoneal dialysis prescription
  • On peritoneal dialysis for more than 3 months
  • Age 18 years or older
Not Eligible

You will not qualify if you...

  • History of type 1 diabetes, diabetic ketoacidosis, brittle diabetes, or frequent severe hypoglycemia requiring emergency intervention in the last 6 months
  • Use of an SGLT2 inhibitor within the prior 30 days
  • One or more episodes of peritonitis in the previous 6 months or active infection of the peritoneal dialysis catheter
  • Anemia with hemoglobin less than 8 g/dL
  • Inability to give written informed consent or follow study protocol
  • Contraindication to receiving loop diuretics

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Yale University

New Haven, Connecticut, United States, 06510

Actively Recruiting

Loading map...

Research Team

V

Veena Rao, PHD

CONTACT

K

Kara Otis

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

OTHER

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here